secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0000950170-24-056292
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NewAmsterdam Pharma Q1 net loss $93.8M; Phase 3 readouts on track for 2024
--------------------------------------------------------------------------

- Enrolled over 9,500 patients in Phase 3 PREVAIL CVOT; topline data from BROOKLYN in Q3 2024 and BROADWAY in Q4 2024.
- Cash position $481.1M at March 31, vs $340.5M Dec 31, bolstered by $190M public offering.
- Net loss $93.8M ($1.06/diluted share) vs $42.0M ($0.51) year ago; revenue fell to $1.4M from $8.6M.
- Dosed first patients in TANDEM (fixed-dose obicetrapib/ezetimibe); topline expected Q1 2025.
- Appointed William H. Lewis as Board Chair and Juliette Audet as Chief Business Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/0000950170-24-056292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000095017024056292/nams-20240509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-056292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer